# A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia

> **NCT05865535** · PHASE1 · RECRUITING · sponsor: **AVEO Pharmaceuticals, Inc.** · enrollment: 30 (estimated)

## Conditions studied

- Cachexia

## Interventions

- **BIOLOGICAL:** AV-380

## Key facts

- **NCT ID:** NCT05865535
- **Lead sponsor:** AVEO Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-13
- **Primary completion:** 2026-12-01
- **Final completion:** 2026-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05865535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05865535, "A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05865535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*